Oxygen Heterocycle Patents (Class 424/78.38)
-
Publication number: 20130344024Abstract: Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof. Drug products including a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof, in combination are also disclosed.Type: ApplicationFiled: August 27, 2013Publication date: December 26, 2013Applicant: Daiichi Sankyo, Inc.Inventor: Michael R. Jones
-
Publication number: 20130336918Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventor: Ardelyx, Inc.
-
Publication number: 20130336920Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventor: Ardelyx, Inc.
-
Publication number: 20130336919Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventor: Ardelyx, Inc.
-
Publication number: 20130336921Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte
-
Patent number: 8580245Abstract: The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P188) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e.g., for treating dystrophin-deficient cells (e.g., myocytes)).Type: GrantFiled: October 29, 2010Date of Patent: November 12, 2013Assignee: The Regents of the University of MichiganInventors: Joseph M. Metzger, Dewayne Townsend, Soichiro Yasuda, Daniel E. Michele
-
Publication number: 20130287725Abstract: A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AaXxYy wherein: A represents a monomer selected from the group consisting of a sugar or —(O—CH2—CH2—CO)—, X represents a carboxyl group bonded to monomer A, Y represents a sulfate or sulfonate group bonded to monomer A a represents the number of monomers A such that the mass of the polymers of formula (I) is greater than approximately 5,000 da, x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.Type: ApplicationFiled: April 12, 2013Publication date: October 31, 2013Inventors: Denis BARRITAULT, Jean-Pierre CARUELLE
-
Publication number: 20130280335Abstract: A biomedical implant according to this invention comprises ceramic complex, which includes a surface-modified basic ceramic particles, which are basic ceramic particles modified their surface with first biodegradable polymers, and the second biodegradable polymers. The first and second biodegradable polymer are combined each other and form a stereo complex. The biomedical implant has a superior effect to suppress inflammation caused by degradation of biodegradable polymers with improving its mechanical property.Type: ApplicationFiled: October 2, 2012Publication date: October 24, 2013Applicant: Korea Institute of Science and TechnologyInventors: Dong Keun HAN, Yoon Ki JOUNG, Jong Hee KANG, Ji Yeon CHOI, Chang Hun KUM
-
Patent number: 8562965Abstract: The invention provides a polymer comprising (i) a first water-soluble polymer segment that is covalently attached, either directly or through one or more atoms, to a first oxygen atom that is covalently attached to a linking carbon atom; (ii) a second water-soluble polymer segment is covalently attached, either directly or through one or more atoms, to a second oxygen atom that is covalently attached to the linking carbon atom; and (iii) a reactive group that is covalently attached, either directly or through one or more atoms, to the linking carbon atom. The invention also provides, among other things, methods for preparing polymers, conjugates, pharmaceutical compositions and the like.Type: GrantFiled: May 3, 2005Date of Patent: October 22, 2013Assignee: Nektar TherapeuticsInventors: Samuel P. McManus, Antoni Kozlowski
-
Publication number: 20130272997Abstract: A biocompatible, polymeric composition is disclosed. The composition comprises a base polymer comprising (i) a prepolymer comprising para-dioxanone (PDO) and trimethylene carbonate (TMC); and (ii) an end-graft polymer chain comprising a polylactone. Also disclosed are a method for treating bleeding from bone or bony structures using the composition, a method for filling a void or correct a defect in a bone using the composition, and a method for producing the biocompatible, polymeric composition of the present application.Type: ApplicationFiled: April 12, 2012Publication date: October 17, 2013Applicant: Poly-Med, Inc.Inventors: Kenneth David Gray, JR., Michael Scott Taylor
-
Publication number: 20130266534Abstract: The invention relates to the field of organic chemistry, pharmacology and medicine and concerns a method for producing a copolymer of sodium carboxymethyl cellulose and gossypol having the formula (I), as well as the use thereof in a combined treatment for patients with autistic spectrum disorders and cognitive impairment.Type: ApplicationFiled: October 6, 2011Publication date: October 10, 2013Applicant: OBSHESTVO S 0RGANICHENNOI OTVETSTVENNOSTYU "NAIRMEDIAK PLUS"Inventors: Felix Ivanovich Ershov, Vladimir Georgievich Nesterenko, Abdushukur Abdukhalilovich Sarymsakov, Natalya Uryevna Alekseeva
-
Patent number: 8545831Abstract: In the present invention, the applicants describe methods and compositions of treating damaged cardiovascular elements and cardiovascular conditions including hypotension, atherosclerotic lesions, vulnerable plaque, and acute myocardial infarct. The applicants demonstrate the ability of a biomembrane sealing agent to accumulate on the walls of damaged blood vessels and help improving mean arterial pressure following tissue injury. The applicants describe the use of formulations comprising at least one biomembrane sealing agent and one bioactive agent for prophylactic treatment such as they could be administered concurrently to an invasive therapeutic intervention or after the insult (i.e. post-injury or post-surgery). Alternatively, these methods and compositions could be used to reduce the severity of cardiovascular diseases after onset.Type: GrantFiled: May 31, 2006Date of Patent: October 1, 2013Assignee: Warsaw Orthopedic, Inc.Inventors: Josee Roy, Hezi-Yamit Ayala, Carol Sullivan, Mingfei Chen
-
Publication number: 20130209392Abstract: The present invention provides cyclic dimers of alpha acids and polymers derived therefrom. Also provided are processes for preparing and methods of using the cyclic dimers and the polymers derived from the cyclic dimers.Type: ApplicationFiled: February 8, 2013Publication date: August 15, 2013Applicant: NOVUS INTERNATIONAL INC.Inventor: Novus International Inc.
-
Patent number: 8507629Abstract: A production method of the present invention is a production method of an organic polymer containing two or more organic ring structures and a chain structure threading through the organic ring structures. This method includes a polymerization step of forming the organic polymer, in which the organic ring structures, which are restricted from moving, are disposed at each of a particular constitutional unit, by polymerizing at least one type of monomers each of which has no ionic functional group that releases a metal ion. The above at least one type of monomers include a monomer (M) containing the organic ring structure and a chain component threading through the organic ring structure.Type: GrantFiled: December 6, 2007Date of Patent: August 13, 2013Assignee: Panasonic CorporationInventors: Takayuki Takeuchi, Norihisa Mino, Nobuaki Kambe, Jun Terao
-
Publication number: 20130195789Abstract: A low swell, long-lived hydrogel sealant formed by reacting a highly oxidized polysaccharide containing aldehyde groups with a multi-arm amine is described. The hydrogel sealant may be particularly suitable for applications requiring low swell and slow degradation, for example, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants; neurosurgery applications, such as sealing the dura; and as a plug to seal a fistula or the punctum. The low swell, long-lived hydrogel sealant may also be useful as a tissue sealant and adhesive, and as an anti-adhesion barrier.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: Actamax Surgical Materials LLCInventor: Actamax Surgical Materials LLC
-
Publication number: 20130177601Abstract: Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone.Type: ApplicationFiled: October 29, 2012Publication date: July 11, 2013Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
-
Patent number: 8466255Abstract: The present invention includes a novel polyethylene glycol derivative; a drug carrier comprising the derivative; and a pharmaceutical composition comprising the drug carrier having a pharmacologically active substance included therein. Specifically disclosed are: a polyethylene glycol derivative represented by the general formula (I); a drug carrier comprising the derivative and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl-glycerol; and a pharmaceutical composition comprising the drug carrier and a pharmacologically active substance (preferably double-stranded RNA, double-stranded DNA or an oligonucleic acid), wherein R represents a saturated or unsaturated aliphatic hydrocarbon group having 10 to 30 carbon atoms or a saturated or unsaturated fatty acid residue having 10 to 30 carbon atoms; and n represents an integer of 30 to 150.Type: GrantFiled: February 4, 2008Date of Patent: June 18, 2013Assignee: Nippon Shinyaku Co., Ltd.Inventors: Satoru Sonoke, Toshihiro Ueda
-
Publication number: 20130122063Abstract: A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.Type: ApplicationFiled: December 18, 2012Publication date: May 16, 2013Applicant: University of Kentucky Research FoundationInventor: University of Kentucky Research Foundation
-
Publication number: 20130101547Abstract: The present specification generally relates to compositions comprising a thermoresponsive polymer and methods of treating a soft tissue condition using such compositions.Type: ApplicationFiled: October 16, 2012Publication date: April 25, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Publication number: 20130095160Abstract: Resorbable biomaterials including polystatin polymers and devices including the resorbable biomaterials are described. Methods of making the resorbable biomaterials and devices including resorbable biomaterials are also described.Type: ApplicationFiled: September 12, 2012Publication date: April 18, 2013Inventors: Gautam S. Ghatnekar, Wayne H. Kaesemeyer
-
Publication number: 20130095161Abstract: The present disclosure relates to compositions A composition comprising a polymerization product of an anionic polysaccharide, a diisocyanate, and a linker, wherein the linker comprises i) an ether group, an ester group, or a combination thereof and, ii) a chain extender comprising a hydroxyl group, a thiol group, an amine group, or a combination thereof. The disclosure further relates to medical devices comprising the aforementioned compositions, and to methods of using the compositions and devices. More particularly, the compositions, devices and methods described herein are useful for preventing protein adhesions in vivo, particularly the Vroman effect.Type: ApplicationFiled: October 5, 2012Publication date: April 18, 2013Inventors: Lukas Bluecher, Michael Milbocker
-
Patent number: 8394393Abstract: A composite material containing polymeric nanofibers, themselves containing NO-donor molecules, imbibed with an elastomer matrix is permeable to both water and gas so that dissociation reactions in the presence of water releases NO gas in a sustained manner. The NO-donor nanofibers may be formed by synthesizing acceptable NO-donor molecules, blending such molecules in solution with PVP, PCL or PVAc, electrospinning the blend at relatively high voltage for form fiber mats, applying PDMS rubber to the fiber mat and crosslinking it. The resulting NO-releasing electrospun fiber composite may be used in medical devices such as catheters, stents, or vascular grafts, with the purpose of releasing nitric oxide within a controlled rate and for a sustained period of time, as well as other known medical applications for NO.Type: GrantFiled: April 6, 2011Date of Patent: March 12, 2013Assignee: Syracuse UniversityInventors: Patrick Mather, Ifeanyi Onyejewke, Kazuki Ishida
-
Publication number: 20130034509Abstract: The present invention relates to a method for the cosmetic treatment of the skin involving a compound, or set of compounds, capable of condensing in situ.Type: ApplicationFiled: December 15, 2010Publication date: February 7, 2013Applicant: L'OREALInventors: Guillaume Cassin, Henri Samain, Didier Candau, Florence L'Alloret, Angelina Roudot
-
Patent number: 8361455Abstract: One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.Type: GrantFiled: April 27, 2006Date of Patent: January 29, 2013Assignees: Pluromed, Inc., The General Hospital CorporationInventors: W. Scott McDougal, Dianne E. Sacco, Alexander Schwarz, Jean-Marie Vogel
-
Patent number: 8349363Abstract: There is provided a new aqueous temperature responsive delivery system made with a temperature responsive polymer and a bioadhesive which is intrinsically cationic. This system may also have an effective amount of a treating agent, which may be a medical or cosmetic agent. The bioadhesive, temperature responsive delivery system is useful in delivering moisturizers or pharmaceutically active agents to the user in controlled release manners, through the tissues in a body cavity.Type: GrantFiled: November 7, 2008Date of Patent: January 8, 2013Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Yanbin Huang, Bashir Musse Sheikh-Ali, Jaeho Kim
-
Publication number: 20120308510Abstract: Articles for increasing lubrication of a joint are described herein. The articles include resorbable, biocompatible particles having a glass transition temperature within a joint of less than about 37° C. and capable of increasing fluid movement within the joint compared to synovial fluid, viscosupplemental fluid, or combinations thereof. A composition for increasing lubrication of a joint is also disclosed. The composition includes the resorbable, biocompatible particles and a carrier fluid. Methods of lubricating a joint and treating disease affecting the joint such as osteoarthritis are also described herein. The methods include introducing the resorbable, biocompatible particles into a joint.Type: ApplicationFiled: June 4, 2012Publication date: December 6, 2012Applicant: MAGUIRE ABBEY, LLCInventor: Joseph P. Laico
-
Publication number: 20120308629Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.Type: ApplicationFiled: August 16, 2012Publication date: December 6, 2012Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Jamie Li, Michael Madden
-
Publication number: 20120308511Abstract: Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof. Drug products including a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof, in combination are also disclosed.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Applicant: Daiichi Sankyo, Inc.Inventor: Michael R. Jones
-
Publication number: 20120288471Abstract: Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH2CH2— group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.Type: ApplicationFiled: November 1, 2011Publication date: November 15, 2012Applicant: Genzyme CorporationInventors: Chad C. Huval, Stephen Randall Holmes-Farley, Pradeep K. Dhal
-
Publication number: 20120282306Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: July 12, 2012Publication date: November 8, 2012Inventors: Scott Eliasof, Thomas C. Crawford, Geeti Gangal, Lawrence Alan Reiter, Pei-Sze Ng
-
Publication number: 20120244108Abstract: In one aspect, methods for separating biological tissue are described herein. In some embodiments, a method for separating tissue comprises providing a first composition comprising a polymerizable material, providing a second composition comprising a polymerization initiator, disposing the first composition at a first site beneath a first tissue layer, disposing the second composition at the first site, polymerizing the polymerizable material at the first site, and separating the first tissue layer from a second tissue layer.Type: ApplicationFiled: March 21, 2012Publication date: September 27, 2012Applicant: Board of Regents, The University of Texas SystemInventors: Jian Yang, Minh-Tuan Richard Tran, Michael W. Palmer, Shou-Jiang Tang
-
Patent number: 8273828Abstract: Biocompatible polymers having polymer backbones with at least one secondary amine suitable for diazeniumdiolation are disclosed. Specifically, methods for providing secondary amines-containing polymers using epoxide-opening reactions are provided. More specifically, nitric oxide-releasing medical devices made using these polymers are disclosed.Type: GrantFiled: July 24, 2007Date of Patent: September 25, 2012Assignee: Medtronic Vascular, Inc.Inventors: Mingfei Chen, Peiwen Cheng, Kishore Udipi
-
Publication number: 20120219626Abstract: The invention relates to a pharmaceutical immediate release tablet comprising a core comprising 70-85 weight percent of sevelamer carbonate, calculated as an anhydrous compound, 10-25 weight percent of lactose monohydrate and, optionally, a water soluble film coat surrounding the to a process of making such tablets, to their use in medicine, and to the use of polyvinyl alcohol-polyethylene glycol graft copolymer for making such coated tablets.Type: ApplicationFiled: October 22, 2009Publication date: August 30, 2012Inventor: Niels Jaap Osinga
-
Publication number: 20120195848Abstract: The present invention provides bioactive bone cements that not only have sufficient radiopacity, low physiological toxicity, and requisite mechanism strength, but also promote local bone in-growth. The bone cement utilizes strontium salts as radiopacifiers, and comprises a powder component and a liquid component. In an embodiment, the powder component comprises a strontium salt, poly(methyl methacrylate) (PMMA), and a polymerization initiator; and the liquid component comprises methyl methacrylate (MMA) as reactive monomers and a polymerization accelerator.Type: ApplicationFiled: December 15, 2011Publication date: August 2, 2012Applicant: The University of Hong KongInventors: William Weijia Lu, Raymond Wing Moon Lam, Keith Dip-Kei Luk, Zhao Yang Li
-
Patent number: 8221735Abstract: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.Type: GrantFiled: April 23, 2009Date of Patent: July 17, 2012Assignee: BioCure, Inc.Inventors: Dennis W. Goupil, Hassan Chaouk, Troy Holland, Bruktawit T. Asfaw, Stephen D. Goodrich, Lucas Latini
-
Publication number: 20120171155Abstract: The present invention relates to compositions having durable antimicrobial activity. The compositions include a carbonate/bicarbonate salt of a quaternary ammonium cation, an organic acid, hydrogen peroxide and a polymer. The polymer is selected from cationic amine polymer-epichlorohydrin adduct, cationic amine polymer-epichlorohydrin resin, poly(methacrylamidopropyltrimethylammonium)chloride, poly(bis(2-chloroethyl)ether-alt-1,3-bis(dimethylamino)propyl)urea, poly(diallyldimethylammonium)chloride, poly(t-butyl acrylate co-ethyl acrylate co-methacrylic acid), polyethylene oxide, polyquaternium-16, polyquaternium-22, polyquaternium-67 and mixtures thereof.Type: ApplicationFiled: December 30, 2010Publication date: July 5, 2012Inventors: Corey T. Cunningham, Rebecca Ann Vongsa, Stacy A. Mundschau, David W. Koenig, Douglas R. Hoffman
-
Publication number: 20120164076Abstract: Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to cancer. In preferred synergistic aspects, the inventive compositions (Thyex-1-6A and -6B) are administered in combination with a macrophage stimulating agent (e.g., beta glucan) for cancer treatment. Certain aspects relate to treating cancer, comprising: administering of a therapeutically effective amount of a thymus extract composition (Thyex-1-6A and -6B) in combination with administration of an extract of Houttuynia cordata. Further aspects comprise administration to a mammalian subject in need thereof a therapeutically effective amount of an extract of Houttuynia cordata, wherein treating or alleviating nausea is afforded. Combination or adjunctive therapies (e.Type: ApplicationFiled: July 2, 2010Publication date: June 28, 2012Applicant: CMI RESEARCH MANAGEMENT, LLCInventor: Richard N. Ushijima
-
Publication number: 20120156164Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.Type: ApplicationFiled: September 2, 2010Publication date: June 21, 2012Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Ki-Dong Park, Yoon-ki Joung, Kyung-Min Park, Eu-Gene Lih
-
Patent number: 8202962Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of: forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polyester production facility to thereby produce the polyester; heating at least a portion of the reaction medium via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water; flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and heating one or more process fluid streams of the polyester production facility via indirect heat exchange with at least a portion of the lower-pressure steam, wherein the process fluid streams include any stream that is formed predominately of the reaction medium and/or the at leaType: GrantFiled: September 11, 2009Date of Patent: June 19, 2012Assignee: Grupo Petrotemex, S.A. de C.V.Inventors: Alan George Wonders, James Donald Simpson, Bruce Roger DeBruin
-
Publication number: 20120148523Abstract: A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized polysaccharide containing pendant aldehyde groups with a water-dispersible, multi-arm amine is described. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a more rapid degradation time, such as the prevention of undesired tissue-to tissue adhesions resulting from trauma or surgery.Type: ApplicationFiled: June 30, 2010Publication date: June 14, 2012Applicant: Actamax Surgical Materials LLCInventors: Helen S.M. Lu, Steven W. Shuey
-
Patent number: 8197849Abstract: A composition comprising a polymer that comprises oxidated hyaluronic acid cross-linked by a dihydrazide is disclosed. The polymer is a hydrogel exhibiting the following properties: a) transparent and colorless; and b) transforming from a liquid state into a gel-matrix at 37° C. These characteristics make it useful as a vitreous humor substitute.Type: GrantFiled: August 31, 2010Date of Patent: June 12, 2012Assignee: National Health Research InstitutesInventors: Feng-Huei Lin, Wen-Yu Su, Yu-Chun Chen, Ko-Hua Chen
-
Patent number: 8198397Abstract: Integrated processes for making polyesters are disclosed, that include the steps of: (a) producing an aromatic polycarboxylic acid in a monomer production facility; (b) producing a polyester in a polyester production facility, wherein the producing of the polyester comprises the substeps of: (i) forming a polyester reaction medium comprising at least a portion of the aromatic polycarboxylic acid from the monomer production facility, (ii) subjecting at least a portion of the polyester reaction medium to one or more chemical reactions to thereby produce the polyester, (iii) heating the polyester reaction medium at one or more locations in the polyester production facility via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water, and (iv) flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and (c) using at least a portion of the lowerType: GrantFiled: September 11, 2009Date of Patent: June 12, 2012Assignee: Grupo Petrotemex, S.A. de C.V.Inventors: Alan George Wonders, James Donald Simpson, Bruce Roger DeBruin
-
Patent number: 8187634Abstract: Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation.Type: GrantFiled: August 31, 2007Date of Patent: May 29, 2012Assignee: USV, Ltd.Inventors: Deepak Anant Hegde, Varsha Shashank Choudhary, Venkatasubramanian Radhakrishnan Tarur, Dhananjay Govind Sathe, Harish Kashinath Mondkar, Samadhan Daulat Patil, Sasikumar Mohan Thoovara, Yogesh Sharad Bhide
-
Publication number: 20120121532Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to. a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: ApplicationFiled: June 1, 2011Publication date: May 17, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Publication number: 20120121704Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.Type: ApplicationFiled: July 14, 2011Publication date: May 17, 2012Applicant: Genzyme CorporationInventors: Hitesh R. Bhagat, Jeffrey M. Goldberg, Abizer I. Harianawala, Louis Brenner
-
Publication number: 20120095558Abstract: A porous, self-sustaining body useful as a scaffold for bone grafting is provided. The scaffold comprises a carbonaceous matrix comprising a continuous phase having a surface and defining a plurality of open spaces throughout the matrix. The internal and external surfaces of the matrix are coated with a layer or film selected from the group consisting of osteogenic materials, therapeutic agents, and combinations thereof. The porous body comprises organic materials and is substantially free of metals. Methods of making and using the porous self-sustaining body are also provided, along with kits for facilitating the same.Type: ApplicationFiled: October 13, 2011Publication date: April 19, 2012Applicant: CIBOR, INC.Inventors: Paul Hastings Wooley, Haiying Yu
-
Publication number: 20120082728Abstract: The present invention relates to the field of drug delivery nanosystems. More precisely, the present invention concerns a copolymer with advantageous properties for the outer coating of various nanoparticles. Said copolymer comprises at least three types of monomers with stealthy, coupling and therapeutic properties respectively, as well as an optional fourth type of monomers with targeting properties. The present invention also relates to core-shell or hollow shell nanoparticles coated by an external layer of the copolymer according to the invention. Several types of core-shell nanoparticles are envisaged. The invention also concerns methods for preparing said nanoparticles, as well as pharmaceutical compositions or medicaments comprising them.Type: ApplicationFiled: January 21, 2010Publication date: April 5, 2012Applicant: UNIVERSITE DE STRASBOURGInventors: Grégory F. Schneider, Gero Decher, Karel Ulbrich, Vladimir Subr
-
Publication number: 20120040002Abstract: Biocompatible and resorbable melt derived glass compositions which include: SiO2 60-70 weight-%, Na2O 5-20 weight-%, CaO 5-25 weight-%, MgO 0-10 weight-%, P2O5 0.5-3.0 weight-%, B2O3 0-15 weight-%, Al2O3 0-5 weight-%, and which contain less than 0.05 weight-% potassium. Biocompatible and resorbable glass fibres manufactured from these glass compositions, medical devices containing fibres of the invention, the use of these compositions for the manufacture of glass fibre and the use of the fibres for the manufacture of medical devices are also disclosed.Type: ApplicationFiled: April 20, 2010Publication date: February 16, 2012Inventors: Timo Lehtonen, Jukka Tuominen, Fredrik Ollila
-
Publication number: 20120023653Abstract: A shaped body suitable for use as acid-releasing body in toilets includes 10-95% of a lactic acid oligomer with an average degree of polymerization between 1.8 and 4. The shaped body provides for the controlled release of lactic acid, which serves to reduce or prevent to the formation of calcium and magnesium deposits in the toilet, contributes to soap scum removal, and has a sanitizing and disinfecting effect. The shaped bodies may be used in-bowl or in-cistern.Type: ApplicationFiled: February 24, 2010Publication date: February 2, 2012Applicant: PURAC BIOCHEM BVInventor: Rudolf Eduard Nijburg
-
Patent number: 8105391Abstract: Provided herein are a method, which comprises implanting in a patient an implantable device comprising a coating that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.Type: GrantFiled: April 1, 2010Date of Patent: January 31, 2012Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Lothar W. Kleiner, Connie S. Kwok